Esoxybutynin

Drug Profile

Esoxybutynin

Alternative Names: S-Oxybutynin

Latest Information Update: 11 Jul 2007

Price : $50

At a glance

  • Originator Sepracor
  • Class Antispasmodics; Small molecules
  • Mechanism of Action Cholinergic receptor antagonists; Muscarinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Urinary incontinence

Most Recent Events

  • 21 Jun 2001 Phase-III clinical trials for Urinary incontinence in USA (PO)
  • 30 Aug 2000 Clinical data have been added to the adverse events and Genitourinary Disorders therapeutic trials sections
  • 23 Jun 2000 Sepracor has successfully completed a phase II dose-ranging trial in the USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top